Whitehawk Therapeutics Inc

WHWK | NASDAQ

Price Alert Chart Builder DCF Calculator

$4.03

-$0.01 (-0.25%)

Sep 22, 2026, 1:13 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-0.25%

(1D)

Rating

Updated: Aug 21, 2026

30.5

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $229.85M

1D Range

4.01 4.17

52W Range

1.82 5.50

Valuation (TTM)

PE -3.61

PB 1.26

EV/EBITDA -0.50

Valuation (NTM)

Forward PE N/A

Forward PEG 0.54

Price Target $8

Cash Flow

FCF Yield -30.1%

SBC Adj. FCF Yield -33.9%

SBC Impact -12.7%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y -78.7% | -9.1%

Dil EPS 3Y | 5Y 54.2% | 52.3%

FCF 3Y | 5Y -10.8% | -8.1%

Returns

ROA -41.1%

ROE -53.9%

ROIC -47.0%

Financial Health

Net Cash

$189.98M

Current Ratio 17.38

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody dru...

Sector Healthcare

Industry Biotechnology

Employees 32

IPO Date Jul 31, 2017

Website ir.whitehawktx.com

Fiscal Year n/a

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 11, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞